D’LIGHT was asked by a client whether the transaction pricing for the sale of medical raw materials between a parent and subsidiary was subject to specific statutes.
D’LIGHT advised the client that statutes concerning medical products lacked any provisions that governed the determination of pricing between related companies. D’LIGHT also advised the client that such transaction between a parent and subsidiary during clinical trials would not be subject to fair-trade regulations, although various tax risks could exist.
